CAR T-cell kinetics and CD22 CAR T-cell persistence in patients with non-CNS EMD. (A) Peak absolute CAR T-cell expansion in patients with non-CNS EMD vs those without non-CNS EMD treated with anti-CD19 (B), anti-CD19/22 (C), and anti-CD22 (D) CAR T cells. For CD22 CAR patients, substantially higher peak CAR T-cell expansion was shown in those with non-CNS EMD (n = 7; median, 2167 cells/mL; range, 105.3-13 653 cells/mL) compared with those without non-CNS EMD (n = 51; median, 573.8 cells/mL; range, 0.65-11 345 cells/mL) (P = .04). CD22 CAR T-cell persistence: (E) ∼1 month (median, 26 days; range, 18-30 days), (F) ∼2 months (median, 58 days; range, 41-69 days), and (G) ∼3 months (median, 94 days; range 84-129 days) after CAR T-cell infusion.